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Abstract
Cancer patients present high mobilization of host protein, with a
decrease in lean body mass and body fat depletion occurring in parallel
to neoplastic growth. Since leucine is one of the principal amino acids
used by skeletal muscle for energy, we investigated the changes in
body composition of pregnant tumor-bearing rats after a leucine-
supplemented diet. Sixty pregnant Wistar rats divided into six groups
were fed a normal protein diet (18%, N) or a leucine-supplemented
diet (3% L-leucine, L). The pregnant groups were: control (CN),
Walker 256 carcinoma-bearing rats (WN), control rats pair-fed with
tumor-bearing rats (pfN), leucine-supplemented (CL), leucine-supple-
mented tumor-bearing (WL), and leucine-supplemented rats pair-fed
with tumor-bearing rats (pfL). At the end of pregnancy, all animals
were sacrificed and body weight and tumor and fetal weight were
determined. The carcasses were then analyzed for water, fat and total,
collagen and non-collagen nitrogen content. Carcass weight was
reduced in the WN, WL, pfN and pfL groups compared to control. The
lean body mass and total carcass nitrogen were reduced in both tumor-
bearing groups. Despite tumor growth and a decrease in fetal weight,
there was a slight decrease in collagen (7%) and non-collagen nitrogen
(8%) in the WL group compared with the WN group which showed a
decrease of 8 and 12%, respectively. Although the WL group pre-
sented severe tumor growth effects, total carcass nitrogen and non-
collagen nitrogen were particularly higher in this leucine-supple-
mented group compared to the WN group. These data suggest that the
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Malignant neoplasias can kill the host
due to fast growth spreading to all tissues and
the intense waste of nutrients, or by a combi-
nation of these factors (1). Cancer cachexia
is characterized by anorexia and host tissue
depletion. More than 80% of the patients
with malignant disease present features of
malnutrition and cachexia as the cause of
death (2). During cancer growth the host
presents hypercatabolism, mainly of protein,
reduced tissue mass and an increasingly nega-
tive nitrogen balance. In many cases, the lean
body mass of tumor-bearing rats decreases
proportionally to the increase of the neoplas-
tic mass (1). A recent experiment has shown
increased leucine oxidation in tumor-bear-
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ing animals, supporting the demand for both
skeletal muscle and tumor tissue, which
seems to contribute to the enhanced amino
acid turnover (3). In the presence of energy
deficiency, tumor cells use other substrates
such as alanine, glutamine, lactic acid and
ketone bodies (4). Maternal nutrition is very
important for the duration of pregnancy. The
physiological changes occurring during preg-
nancy can be sustained by an appropriate
nutrient supply to ensure placental and fetal
development (5). The association between
cancer and pregnancy is about 0.1% (6).
Cancer development is difficult to predict
and its diagnosis is delayed due to the pe-
riod, evolution and term of pregnancy (5). In
fact, some studies have suggested that preg-
nancy does not favor the development of
cancer, but protects the organism against
tumor growth (7). In contrast, recent studies
have shown fetal reabsorption and death
during the evolution of malignant Walker
tumor (8). Protein is intensely mobilized in
the organism with cancer, a fact leading to
the cachectic state. On the other hand, dur-
ing the early stages of rat pregnancy, protein
is synthesized and accumulated in the mater-
nal organism and is later mobilized during
the last days of pregnancy to provide sub-
strates for the fetus (9). To some extent, the
fetus can be compared to rapid tumor growth
since both tissues have an exponential growth
and are dependent on an adequate supply of
glucose and amino acids. For this reason, the
association between cancer and pregnancy
may change the nutritional supply to both
tumor and fetal tissues. Furthermore, several
studies have reported that the branched chain
amino acid leucine independently stimulates
skeletal muscle protein synthesis and that
enhanced oxidation can prevent alanine re-
lease by skeletal muscle (10). Thus, the aim
of the present study was to investigate the
effect of a leucine-supplemented diet on
chemical body composition during tumor
growth in pregnant rats.
Young female Wistar rats (45 days old, N
= 60) were obtained from the State Univer-
sity of Campinas animal facility, and main-
tained in the Nutrition and Metabolism Re-
search Laboratory of the Department of Phys-
iology and Biophysics of UNICAMP. Fe-
male rats were placed with adult males (90-
100 days old, 4 females: one male) in collec-
tive cages for one night (12 h) according to
the harem method. The first day of preg-
nancy was determined following detection
of sperm in a vaginal smear. Animals were
housed in metabolic cages under normal con-
ditions (22 ± 2oC, 12/12-h light/dark cycle).
All animals were fed ad libitum a semipuri-
fied AIN-G93 diet with free access to drink-
ing water throughout the experiment. Pair-
fed non-tumor-bearing controls were offered
the same amount of food as that eaten by the
tumor-bearing rats. The pregnant animals
were divided into six groups and studied for
20 days. Three groups were fed a normal
protein diet (18% protein, AIN-G93; N):
control rats (CN), tumor-bearing rats (WN),
and control pair-fed to tumor-bearing groups
(pfN). The other three groups were fed the
leucine diet (15% protein and 3% L-leucine,
according to AIN-G93; L): control rats fed
the leucine-supplemented diet (CL), tumor-
bearing rats fed the leucine-supplemented
diet (WL), and leucine pair-fed groups (pfL).
A Walker 256 tumor cell suspension (ap-
proximately 0.25 x 106 cells in 0.5 ml of
saline) was subcutaneously injected on the
right flank of the WN and WL rats, and the
control groups (CN, CL, pfN and pfL) were
injected with 0.5 ml 0.9% NaCl without
anesthesia. The tumor cells were injected
immediately after pregnancy was detected.
General UKCCR guidelines (1988 United
Kingdom Coordinating Committee on Can-
cer Research) for animal welfare were fol-
lowed (Ethical Committee for Animal Re-
search, CEEA and COBEA, Brazil, No. 034-
2). During the experimental period, changes
in body weight, tumor weight, and food in-
take were recorded every two days. Tumor
weight was calculated from 3 orthogonal
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linear measurements and compared with the
data from a weight dimension curve (8).
After 20 days, all rats were killed by cervical
dislocation. Placental, fetal and tumor weight
were recorded. Gastrointestinal tract, fetuses,
placentas, uterine tissues and tumor mass
were removed, and all carcasses were kept at
-20ºC for chemical analysis of body compo-
sition. The amount of carcass water was
determined by subtracting dry weight from
wet weight. Total fat was extracted with
petroleum ether using a soxlet apparatus. An
aliquot of the carcass after dry and fat extrac-
tion was analyzed for total nitrogen content
using a colorimetric micro-Kjeldahl method
(11). Another sample was submitted to alka-
line digestion with sodium hydroxide plus
acidified tannic acid. After these procedures,
collagen nitrogen was measured by the col-
orimetric method described by Albanese and
Orto (11). Non-protein nitrogen was calcu-
lated by subtracting collagen nitrogen from
total nitrogen. Statistical differences between
groups were assessed by Kruskal-Wallis one-
way analysis of variance (12) followed by
the Dunn test, with the level of significance
set at P<0.05.
At the end of the experiment all pregnant
rats presented a gain in body weight com-
pared to that observed at the beginning of the
experimental period. Even during pregnancy,
when maternal adaptations cause a weight
gain, tumor growth induced a reduction in
body weight (10% in WN and 15% in WL,
P<0.005; Table 1) compared to the control
groups. These results agree with those ob-
tained in studies on CO/COBS rats bearing
Walker 256 tumor for 14 days, which have
shown a 20% reduction in food intake and a
15% reduction in body weight (13). In a
previous study (8) we detected a 12% body
weight reduction in adult pregnant tumor-
bearing rats after 21 days. Although the de-
crease in body weight percentage in both
tumor-bearing groups was similar to that
reported in other studies, food intake was
greatly decreased in these groups (around
32% in the WN and WL groups, data not
shown).
Cancer cachexia is a complex syndrome in
which, besides fat depletion, the progressive
body weight loss occurs mainly because of the
wasting of protein tissue (14). Parallel to a
greater tumor mass, similar in both tumor-
bearing groups independently of diet treat-
ment (Table 1) and a progressive tumor/car-
cass weight ratio in WN and WL (around 7%
in both groups), there was a marked decrease
in fetal weight in both tumor-bearing groups
(57% in WN and 67% in WL; Table 1). These
results also support the idea of a harmful effect
of tumor burden especially during pregnancy
because tumor implantation caused marked
changes in the ratio between placental and
Table 1 - Body and carcass weight, body gain, tumor and fetal weight of the pregnant groups studied.
Data are reported as means ± SEM for 10 animals per group. Groups: control (CN); bearing a Walker 256 carcinoma (WN); control pair-fed to tumor-
bearing groups (pfN); control receiving a leucine-supplemented diet (CL); tumor-bearing rats receiving a leucine-supplemented diet (WL), and
leucine pair-fed groups (pfL). #Carcass weight represents the total body weight minus placentas, fetus, uterus, intestinal tract and tumor tissue.
*P<0.05 compared to control groups; **P<0.05, CN vs CL or WN vs WL (Kruskal-Wallis test followed by the Dunn test).
CN WN pfN CL WL pfL
Body weight on the first day (g) 140.6 ± 4.92 172.9 ± 7.93* 153.1 ± 2.78 146.2 ± 4.71 162.6 ± 7.56 149.8 ± 5.96
Body weight on the last day (g) 231.0 ± 10.25 221.0 ± 8.01 170.1 ± 8.41* 207.2 ± 8.62 226.4 ± 13.02 146.3 ± 8.20*
Carcass weight (g)# 172.7 ± 2.66 166.1 ± 7.21 140.1 ± 6.35* 160.1 ± 3.14 165.4 ± 9.34 120.0 ± 6.81*
Body weight gain on the last day (%) 165.5 ± 8.55 128.9 ± 4.52* 111.8 ± 6.53* 141.9 ± 5.06** 135.2 ± 7.03** 98.18 ± 5.72*
Tumor weight (g) 11.73 ± 0.93 11.58 ± 0.68
Fetal weight (g) 3.73 ± 0.13 1.61 ± 0.22* 2.98 ± 0.34* 3.45 ± 0.16 1.15 ± 0.16 2.77 ± 0.28*
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fetal weight. In the WN group, the fetal weight
decrease was positively correlated with the
placental weight decrease (P<0.01; data not
shown) and therefore the nutritional support to
fetal growth could be due to reduced placental
function. This idea is supported by the fact that
fetal weight reduction was less intense during
nutritional deficiency, such as that observed in
both pfN and pfL groups (a 20% fetal weight
decrease). In addition, the leucine-supple-
mented diet associated with tumor growth
induced a reduction in fetal and placental
weight similar to that observed in the WN
group.
Despite the reduction in fetal weight in-
duced by the leucine-enriched diet, there
was no correlation between the placental
and fetal weight, suggesting that other
mechanisms may be involved in the harm to
the maternal unit. Previous studies have
shown that tumor implantation reduces pla-
cental and fetal weight and protein content in
the placenta and fetus of adult tumor-bearing
rats (8), and produces intensive hemorrhage
and edema in the placenta of tumor-bearing
rats (15). In contrast, the implantation of
Yoshida AH-130 ascites hepatoma during
the last week of rat gestation resulted in
normal fetal growth (16). In most studies,
the percentage of carcass water was higher
in cancer patients (17). The body water con-
tent was slightly increased in the WN, WL
(6% and 7%, respectively) and pair-fed
groups (6% in pfN and 9% in pfL). There-
fore, our data suggest that the changes pro-
duced by tumor growth in these pregnant
rats do not support the alterations in body
water content observed in cancer patients
and in animals (18). The fat carcass decrease
observed in both tumor-bearing groups (32%
in WN and 20% in WL) may have been due
to the intense fat mobilization from adipose
tissue especially in the WN group.
Depletion of host fat stores is a common
finding in cancer cachexia. In an extensive
review (14), this loss of body fat was related,
in part, to a circulatory lipid-mobilizing fac-
tor derived from the tumor cells. Although
anorexia is common in cancer, loss of car-
cass fat cannot be attributed to a decreased
calorie intake alone, since pair-fed animals
do not lose as much fat as tumor-bearing
rats. In contrast, we observed that the de-
crease in body fat was similar in both tumor-
bearing and pair-fed rats. This was possibly
related to the catabolic phase during the last
days of the rat pregnancy. In pregnant rats,
body fat accumulation reaches a maximum
at 19 days of gestation and declines on the
21st day, but several fat depot changes are
highly dependent on the animals feeding
condition, since they change in magnitude
and even in direction in the fasting state (19).
A slight decrease in lean body mass, which
was not significant, was observed in the WN
group (Table 2).
Other studies have shown a significant
increase in proteolysis in cancer patients,
twice as high as observed in malnourished
patients. This wasting of lean body mass
reveals the incapacity to conserve body pro-
tein (20). In contrast, the WL group pre-
sented a slight increase in lean body mass
compared with its respective control group.
However, the increase in WL lean body mass
was significantly higher than in the WN
group (around 12%), suggesting an improved
effect of the leucine-enriched diet. In spite of
a slight (not significant) decrease in total
carcass nitrogen in both tumor-bearing groups
(Table 2), the WL group kept the total nitro-
gen level (13% higher than in the WN group)
even during the wasting of tumor growth.
Collagen nitrogen represents the extracellu-
lar mass that can be less metabolically active
and less wasted than the cellular mass. The
collagen nitrogen was preserved in the WN
group compared to the WL group, which
presented a significant decrease in this pa-
rameter compared to the CL group (Table 2).
Carbo et al. (16) suggested that preg-
nancy could protect against the cachexia
induced by the tumor or retard its appear-
ance. The authors found a similar increase in
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proteolytic rates in both tumor-bearing preg-
nant and virgin rats, but in spite of a great
reduction in both protein synthesis and deg-
radation in the tumor-bearing groups, these
changes were similar to those observed in
the control pregnant groups. Cohn et al. (17)
reported that non-collagen nitrogen repre-
sents the cellular mass and during pathologi-
cal states there is a preferential mobilization
of this protein store.
In the present study, we found a signifi-
cant reduction in non-collagen nitrogen only
in the WN tumor-bearing group (around 11%;
Table 2). In contrast, WL rats presented a
13% higher non-collagen nitrogen level than
WN, suggesting that the waste in body nitro-
gen was lower in the leucine-supplemented
group. Although collagen nitrogen was de-
creased in the WL group, non-collagen ni-
trogen was maintained in these animals, sug-
gesting that leucine supplementation provid-
ed a substrate to preserve the nitrogen car-
cass. Peripheral muscle wasting may be due
to increased muscle catabolism, decreased
protein synthesis, or a combination of the
two (14). While there appears to be an over-
all decrease in the synthesis of muscle pro-
tein in cancer patients, there is an increase in
whole-body protein turnover leading to an
elevated endogenous protein breakdown and
oxidation of amino acids. In addition, amino
acid requirements are altered in the tumor-
bearing state. Host leucine requirements have
been shown to be increased in the presence
of a rapidly growing tumor. Some malignant
cells have specific requirements for essen-
tial amino acids. Removal of one amino acid
by the tumor would lead to a depression of
host protein synthesis (14). For this reason,
since normal synthesis requires the full
complement of amino acids, we may suggest
that supplementation with one amino acid
(for example, leucine) probably supported
the high rates of muscle oxidation, contrib-
uting to the decreased output of some amino
acids from skeletal muscle, which could be
used by neoplastic cells. Further studies are
currently underway to find out whether leu-
cine supplementation could be of benefit to
the host carcass by reducing peripheral tis-
sue mobilization.
Acknowledgments
The authors are indebted to Prof. Michael
J. Tisdale for suggestions and English re-
view and Dr. Juvenal Marcondes Neto for
computing assistance. The authors are also
grateful to Ajinomoto Interamericana Ind. e
Com. Ltda. for providing L-leucine, to Corn
Products Brasil Ingredientes for providing
cornstarch and Roche Industriais e Química
S.A. for providing the vitamin mix.
Table 2 - Body water content, body fat, lean body mass, total carcass nitrogen, and collagen and non-collagen nitrogen content of the pregnant
groups studied.
Data are reported as means ± SEM for 10 animals per group. See Table 1 for group abbreviations. *P<0.05 compared to the respective control
groups; **P<0.05 compared to the WN group (Kruskal-Wallis test followed by the Dunn test).
CN WN pfN CL WL pfL
Body water (%) 56.81 ± 1.46 60.85 ± 1.73 59.39 ± 0.58 56.79 ± 2.55 59.46 ± 1.46 61.31 ± 0.54
Body fat (%) 13.49 ± 0.68 9.10 ± 1.79* 8.07 ± 0.87* 15.07 ± 2.17 12.07 ± 1.62 5.56 ± 0.42*
Lean body mass (g) 39.54 ± 0.86 37.71 ± 1.46 37.53 ± 1.44* 39.24 ± 0.90 42.22 ± 1.45** 33.05 ± 1.93*
Total nitrogen (mg/100 g 65.61 ± 3.10 60.29 ± 3.58* 63.90 ± 4.32 69.74 ± 4.10 68.27 ± 3.47** 54.21 ± 1.70*
carcass weight)
Collagen nitrogen (mg/100 g 5.68 ± 0.53 6.96 ± 0.42* 7.08 ± 0.50 8.57 ± 0.55* 6.82 ± 0.77* 6.48 ± 0.75
carcass weight)
Non-collagen nitrogen (mg/100 g 59.82 ± 3.10 53.33 ± 4.21* 56.87 ± 4.49 61.17 ± 3.89 60.27 ± 4.34** 47.73 ± 1.71*
carcass weight)
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